US3390179A - Novel 10, 11-dihydro-10, 11-dihydroxy-(3-substituted aminopropylidene)-5h-dibenzo [a, d] cycloheptenes - Google Patents

Novel 10, 11-dihydro-10, 11-dihydroxy-(3-substituted aminopropylidene)-5h-dibenzo [a, d] cycloheptenes Download PDF

Info

Publication number
US3390179A
US3390179A US296463A US29646363A US3390179A US 3390179 A US3390179 A US 3390179A US 296463 A US296463 A US 296463A US 29646363 A US29646363 A US 29646363A US 3390179 A US3390179 A US 3390179A
Authority
US
United States
Prior art keywords
dibenzo
dihydro
trans
dihydroxy
cycloheptene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US296463A
Inventor
Howard B Hucker
Marcia E Christy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to US296463A priority Critical patent/US3390179A/en
Priority to SE09743/67A priority patent/SE332820B/xx
Priority to IL21665A priority patent/IL21665A/en
Priority to IL29677A priority patent/IL29677A/en
Priority to GB35404/66A priority patent/GB1074085A/en
Priority to GB35402/66A priority patent/GB1074083A/en
Priority to GB28412/64A priority patent/GB1074082A/en
Priority to GB35403/66A priority patent/GB1074084A/en
Priority to BR160953/64A priority patent/BR6460953D0/en
Priority to BE650800D priority patent/BE650800A/xx
Priority to SE8875/64A priority patent/SE320963B/xx
Priority to SE09742/67A priority patent/SE332819B/xx
Priority to CH953364A priority patent/CH494731A/en
Priority to DK362064AA priority patent/DK127723B/en
Priority to CH1882968A priority patent/CH476677A/en
Priority to DE19641468339 priority patent/DE1468339A1/en
Priority to CH1882868A priority patent/CH490321A/en
Priority to FR1572128D priority patent/FR1572128A/fr
Priority to NL6408390A priority patent/NL6408390A/xx
Priority to ES0302593A priority patent/ES302593A1/en
Priority to FR992062A priority patent/FR3905M/fr
Priority to DK351165AA priority patent/DK121757B/en
Priority to DK351265AA priority patent/DK121856B/en
Priority to US723964*A priority patent/US3576823A/en
Application granted granted Critical
Publication of US3390179A publication Critical patent/US3390179A/en
Priority to US48478A priority patent/US3660389A/en
Priority to DK168772A priority patent/DK130736B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems

Definitions

  • This invention relates to derivatives of dibenzocycloheptenes.
  • the invention relates to 10,11- dihydro-10,1l-dihydroxy-S (3 substituted aminopropylidene)-5H-dibenzo[a,d] cycloheptenes and methods of preparing the same.
  • the invention also relates to intermediates useful in the preparation of the above compounds, as well as processes for the preparation of said intermediates.
  • R is a lower alkyl radical, straight or branched chain, preferably having up to 6 carbon atoms
  • R is a lower alkyl radical, straight or branched chain, preferably having up to 6 carbon atoms
  • X and X which may be siimlar or dissimilar, are hydrogen, an alkyl group having up to 6 carbon atoms, an alkenyl group having up to 6 carbon atoms, halogen, triiluoromethyl, hydroxyl, an alkoxy group having up to 4 carbon atoms, mercapto, an alkylmercapto group having up to 4 carbon atoms, an alkylsult'onyl group having up to 4 carbon atoms, sulfamoyl, an alkylsulfamoyl group having up to 4 carbon atoms or a dialkylsulfamoyl group having up to 8 carbon atoms.
  • the radicals R and R may be similar or dissimilar and they may be linlced together through an atom of carbon, nitrogen or oxygen to form a heterocyclic ring having from five to six atoms therein such as 1piperidyl, l-pyrrolidyl, 4-morpholinyl and l-lower alkyl-4-piperazinyl, the lower alkyl substituent of the latter preferably having up to 4 carbon atoms.
  • the compounds represented by the above structural formulae may also have substituents on the propylidene side chain such as lower alkyl radicals, preferably having from 1 to 4 carbon atoms.
  • anti-depressants they may be administered orally in the form of tablets, powders, sustained release pellets and the like, or they may be administered orally or parenterally in the form of aqueous solution or suspensions. When administered orally or parenterally, satisfactory results are obtained at a daily dosage level of from about mg. to about 1,000 mg, preferably given in divided doses over the day or in sustained release form.
  • the compounds are preferably administered in the form of their non-toxic acid addition salts and these salts are included within the scope of this invention.
  • the compounds represented by the above structural formulae exist as geometric isomers, which are determined by the steric relationships of the hydroxyl groups to each other. In order to prepare the separate isomers, it is necessary to employ an appropriate starting material in the same isomeric form as that desired of the end product.
  • trans isomer of the compounds represented structurally above a trans 3a,12 3dihydro-8H dibenzo[3,4:6,7]cyelohepta[1,2 d]- 1,3-dioxol-8-one is employed, whereas the cis isomers are prepared starting with a cis 10,11-dihydro-10,11-diacyloxy- SH-dibenzo[a,d1cyclohepten-5-one.
  • the desired ketone is treated with a Grignard reagent, namely, a tertiary aminopropylmagnesium halide and the Grignard adduct obtained hydrolylzed to form the corresponding S-hydroxy-S-(S- tertiary aminopropyl) derivative.
  • a Grignard reagent namely, a tertiary aminopropylmagnesium halide
  • the Grignard adduct obtained hydrolylzed to form the corresponding S-hydroxy-S-(S- tertiary aminopropyl) derivative.
  • This is then dehydrated to form the corresponding 5-(3-tertiary aminopropylidene) derivative, which is then either hydrolyzed to form the cis or trans 10,11-dihydr0xy compounds represented by structural Formula I or dealkylated and then hydrolyzed to form the cis or trans 10,11-dihydroxy compounds represented by structural Formula II.
  • Those starting compounds, wherein at least one of X and X is other than hydrogen may be prepared from the corresponding nuclearly substituted H dibenzo[a,d]cyclohepten-5-one utilizing the procedure of G. L. Buchanan and D. B. Jhaveri, referred to above.
  • the latter compounds may be prepared following the teachings of T. W. Campbell et al. in an article appearing in Helv. Chem. Acta, vol. 36, pp. 1489-1499 (1953).
  • the Grignard reagent employed in Step A of the above process may be prepared by known procedures, but it has been found that it may be prepared in high yields as follows:
  • the reaction With the Grignard reagent (Step A) is preferably initially carried out under cooled conditions such as by the use of an ice-bath, and finally may continue at room temperature. It has been found that tetrahydrofuran is a suitable solvent for carrying out the reaction and, accordingly, the ketone may be added directly to the reaction mixture in Which the Grignard reagent was prepared. However, any inert solvent for the reactants may be employed.
  • the bulk of the solvent is removed by vacuum distillation, the Grignard adduct dissolved in a suitable solvent such as benzene, and hydrolyzed by the addition of water or ammonium chloride solution with cooling.
  • the product is recovered by evaporation of the solvent after the removal of any residual inorganic material by filtration.
  • Step B Conversion of the carbinol to the corresponding 5-(3-tertiary aminopropylidene) derivative (Step B) is effected by dehydration.
  • the dehydration may be effected in conventional manner employing such commonly used dehydrating agents as acetyl chloride, acetic anhydride or thionyl chloride.
  • the alcohol may be dehydrated directly or may be first converted to a salt such as the hydrochloride, hydrobromide or sulfate. Conversion to the salt prior to dehydration may be preferable in some cases.
  • the reaction may be carried out at elevated temperatures, and in an excess of dehydrating agent or a solvent such as chloroform or glacial acetic acid may be employed.
  • the desired product is recovered after rendering the mixture alkaline by extraction with a suitable solvent, and then removing the solvent.
  • Step C Conversion of the compound obtained from Step B to the corresponding trans 10,11-dihydroxy compound (Step C) is effected by hydrolyzing the former in an inert solvent, preferably at elevated temperatures, and in the presence of an acidic catalyst such as, for example, p-toluenesulfonic acid, concentrated sulfuric acid, trifiuoroacetic acid, dry hydrochloric acid and the like.
  • an acidic catalyst such as, for example, p-toluenesulfonic acid, concentrated sulfuric acid, trifiuoroacetic acid, dry hydrochloric acid and the like.
  • Any number of inert solvents may be utilized, but it is preferred to employ a lower alkanol such as methanol, ethanol, isopropanol and the like.
  • the product may be recovered by filtration and washed free of any residual acid and further purified by conventional methods.
  • the product is soluble in the solvent employed, it may be recovered by evaporation of the solvent,
  • the trans 10,11-dihydroxy compounds represented by structural formula II may be prepared from the corre sponding 5-(3-dialkylaminopropylidene) compound obtained in Step B above.
  • the alkyl substituents attached to the nitrogen atom be the same. This is readily accomplished by appropriate selection of the Grignard reagent used to prepare the carbinol from which the tertiary aminopropylidene compound is derived. This process may be illustrated as follows:
  • Step D of the above process involves the condensation of the tertiary amino compound with a haloformate to form the corresponding urethane intermediate.
  • a solvent include the aromatic hydrocarbons such as benzene and toluene aliphatic hydrocarbons such as heptane and hexane, and the halogen hydrocarbons such as chloroform and carbon tetrachloride.
  • the reaction may be carried out at room temperature, although an elevated temperature is preferred.
  • the urethane is recovered, after removal of impurities, by evaporation of the solvent.
  • the urethane intermediate thus produced is then subjected to hydrolyysis (Step E).
  • the hydrolysis preferably may be carried out under basic conditions.
  • the desired product is recovered in conventional manner, such as by extraction into a suitable solvent and evaporation of the solvent. Conversion to the corresponding 10,1l-dihydroxy compound is accomplished using the procedure outlined in Step C.
  • the dealkylation may be accomplished by treatment of the tertiary aminop-ropylidene compound with a cyanogen halide to form the corresponding cyanamide intermediate, and the cyanamide thus produced hydrolyzed to the corresponding secondary amine.
  • This process may be illustrated as follows:
  • Step 0 The tertiary amine is dissolved in a non-hydroxylic solvent such as benzene or ether and the solution slowly added to a solution of cyanogen halide in the same solvent, while stirring and permitting the alkyl halide to escape. After the reaction is complete, the basic material is separated by Washing with dilute acid and the cyanamide isolated by evaporating the solvent. The cyanamide is hydrolyzed to the secondary amine in an alkaline medium, and the product recovered in conventional manner. Conversion to the corresponding 10,11-dihydroxy compound is accomplished using the procedure outlined in Step C.
  • the starting compound, wherein X and X are both hydrogen and Ac is acetyl, may be prepared in the manner described by J. Rigaudy and L. Nedelec, Bull. Soc. Chim., France (1960), pgs. 400-405.
  • Those starting compounds, wherein at least one of X and X is other than hydrogen may be prepared from the corresponding nuclearly substituted SH-dibenzo[a,d]cyclohepten-5- one utilizing the procedure of J. Rigaudy et a1. previously mentioned.
  • Those starting compounds, wherein Ac is other than acetyl may be prepared from the corresponding diol by treatment with an appropriate acylating agent following the procedure described by J. Rigaudy et al., above cited, for the preparation of the 10,11-di'acetoxy derivative.
  • the preparation of the Grignard reagent, the reaction with the Grignard reagent (Step A), and dehydration of the resulting carbinol (Step B), may be carried out as previously described herein.
  • the hydrolysis of the 10,11-diacyloxy compound to the corresponding cis 10,11-dihydroxy compound differs from that described for the preparation of the trans 10,11- dihydroxy compounds in that the hydrolysis is effected under alkaline conditions such as by the use of potassium hydroxide and the like.
  • Recovery of the product can be accomplished as described in Step C above, except that neutralization with alkali is unnecessary.
  • Osmium tetroxide 2. Hydrolysis CIIGI-IzCHzN X i l R UHCI-HCH N This process involves treating a -(3-tertiary aminopropylidene) 5H dibenzo[a,d]cycloheptene with an equimolar amount of osmium tetroxide and then hydrolyzing the resulting osmic ester.
  • the reaction with the tetroxide is preferably carried out at room temperature and in a dry, inert solvent in which the osmium tetroxide is soluble.
  • a particularly suitable solvent is dry benzene.
  • a catalyst is employed to facilitate the reaction, and pyridine is suitable for this purpose.
  • the osmic ester which precipitates out may be recovered by filtration.
  • Hydrolysis of the ester to the desired product is conveniently efifected in an aqueous, inert organic solvent such as an aqueous alkanol, preferably ethanol.
  • the hydrolysis is preferably carried out at reflux temperature and in the presence of a suitable reducing agent such as sodium sulfite.
  • the reducing agent is employed for the purpose of recovering the osmium which precipitates out in metallic form. After removal of the metallic osmium by filtration, the product is readily recovered in conventional manner.
  • the 5 (3-tertiary aminopropylidene)-5H-dibenzo[a,d] cycloheptene employed in the process may be readily obtained by treating the appropriately substituted 5H- dibenzo[a,d]cycloheptn-S-one with a Grignard reagent, namely, tertiary aminopropyl magnesium halide, hydrolyzing the resulting Grignard adduct to form the corresponding carbinol and dehydrating the latter, as described in the literature.
  • a Grignard reagent namely, tertiary aminopropyl magnesium halide
  • the preparation of the cis 10,11-dihydroxy compounds represented by structural Formula II may be accomplished by dealkylating the corresponding cis 10,11 diacyloxy-5-(3-dialkyylaminopropylidene) derivative in the same manner as described for the dealkylation of the trans 5-(3-dialkylaminopropylidene) derivative, as described in Steps D and E above. This process may be illustrated as follows:
  • the compounds of this invention may exist as geometric isomers with respect to the hydroxyl substituents only or with respect to both the hydroxyl substituouts and the propylidene side chain, the following procedure for desigating the isomers hereinabove and in the examples and claims which follow has been employed.
  • isomers exist only with respect to the hydroxyl substituents, the designation of the particular isomer precedes the name of the compound.
  • isomers exist as to both the hydroxyl substituents and the propylidene side chain, the designation of the isomers immediately precedes the substituent to which it refers.
  • the benzene layer is decanted from the gelatinous precipitate which then is extracted with four 100 ml. portions of boiling benzene.
  • the combined benzene extracts are washed with water and extracted with three 100 ml. portions of 0.5 M citric acid.
  • the acid extract is made basic with sodium hydroxide, and the oily base that separates is extracted into benzene.
  • the benzene is evaporated and the product obtained as a viscous yellow oil in a yield of 29.5 g. (96%
  • the base may be converted to the hydrogen oxalate salt by treating an ethereal solution with a solution of oxalic acid excess) in isopropyl alcohol.
  • the solution is evaporated to dryness under reduced pressure and the residual syrup dissolved in 30 ml. of water. After one extraction with hexane, the aqueous layer is rendered alkaline with sodium hydroxide and the oily base extracted into benzene. The washed benzene extract is evaporated under reduced pressure, leaving the product as an oily residue weighing, typically, 950 mg. Treatment of an ethereal solution of the base with a solution of 300 mg. of oxalic acid in 3 ml.
  • the base may be converted to the hydrogen oxalate salt by treating an ethanolic solution with a solution of oxalic acid (10% excess) in absolute ethanol.
  • EXAMPLE 17 Cis 10,11-diacetoxy-10,11-dihydro-5-(3-dimethy1aminopropylidene) -5Hdibenzo [a,d] cycloheptene
  • a solution of cis 10,11-diacetoxy-10,11-dihydro-5-(3- dimethylaminopropyl) 5 hydroxy 5H dibenzo[a,d] cycloheptene (19.5 g., 0.0475 mole) in 300 ml. of acetic anhydride is heated to refluxing for 4 hours. The solution is evaporated to dryness under reduced pressure and the residual oil partitioned between 0.5 M citric acid and benzene.
  • the aqueous acid layer is rendered alkaline with sodium hydroxide and the oily base extracted into benzene. Evaporation of the washed and dried benzene extract leaves the product as an oily residue weighing, typically, 18.0 g. (96.5%).
  • the base may be converted to the hydrogen oxalate salt by treating an ethanolic solution with a solution of oxalic acid (10% excess) in absolute ether.
  • Cis 10,11-diacetoxy- 10,11 dihydro 5-(3-dimethylaminopropylidene)-5H-dibenz[a,d]cycloheptene hydrogen oxalate precipitates as a white crystalline solid which melts at 165-166" C. after one recrystallization from a mixture of absolute ethanol and absolute ether.
  • n-butyl alcohol is stirred and heated to refluxing in a nitrogen atmosphere for 6 hours.
  • the solvent is distilled under reduced pressure and the residue partitioned between benzene and water.
  • the combined benzene extracts are washed with water and then extracted with 15 ml. and 10 ml. portions of 0.5 M citric acid.
  • the acid extract is rendered alkaline with sodium hydroxide and the oily base extracted into benzene.
  • the washed and dried benzene extract is concentrated to a small volume.
  • the product separates as a white crystalline solid and is collected, washed with benzene, and dried to obtain 1.05 g. (47% M.P. 140-143 C.
  • the pure product from another experiment melts at 143-145 C. after repeated crystallizations from benzene and from mixtures of ethanol and water.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Description

United States Patent Oifice 3,393,179 Patented June 25, 1968 NOVEL 10,11 DIHYDRO 10,11 DIHYDROXY (3- SUBSTITUTED AMINOPROPYLIDENE) 5H DI- BENZO[a,d]CYCLOHEPTENES Howard B. Hacker, Horsham, and Marcia E. Christy, Colernar, Pa, assignors to Merck & C0., Inc., Railway, N.J., a corporation of New Jersey N Drawing. Filed July 22, 1963, Ser. No. 296,463
4 Claims. (Cl. 260-5703) This invention relates to derivatives of dibenzocycloheptenes. In particular, the invention relates to 10,11- dihydro-10,1l-dihydroxy-S (3 substituted aminopropylidene)-5H-dibenzo[a,d] cycloheptenes and methods of preparing the same. The invention also relates to intermediates useful in the preparation of the above compounds, as well as processes for the preparation of said intermediates.
The end compounds embraced within the scope of the present invention may be represented by the following wherein R is a lower alkyl radical, straight or branched chain, preferably having up to 6 carbon atoms; R is a lower alkyl radical, straight or branched chain, preferably having up to 6 carbon atoms and X and X, which may be siimlar or dissimilar, are hydrogen, an alkyl group having up to 6 carbon atoms, an alkenyl group having up to 6 carbon atoms, halogen, triiluoromethyl, hydroxyl, an alkoxy group having up to 4 carbon atoms, mercapto, an alkylmercapto group having up to 4 carbon atoms, an alkylsult'onyl group having up to 4 carbon atoms, sulfamoyl, an alkylsulfamoyl group having up to 4 carbon atoms or a dialkylsulfamoyl group having up to 8 carbon atoms. More than one of these substituents may be on each of the benzenoid rings. The radicals R and R may be similar or dissimilar and they may be linlced together through an atom of carbon, nitrogen or oxygen to form a heterocyclic ring having from five to six atoms therein such as 1piperidyl, l-pyrrolidyl, 4-morpholinyl and l-lower alkyl-4-piperazinyl, the lower alkyl substituent of the latter preferably having up to 4 carbon atoms.
The compounds represented by the above structural formulae may also have substituents on the propylidene side chain such as lower alkyl radicals, preferably having from 1 to 4 carbon atoms.
Representative end compounds incompassed within the scope of the present invention include:
10,11-dihyd-ro-10,1l-dihydroxy-S-[3-(1-piperidyl)- propylidene] -5H-dibenzo a,d] cycloheptene 10,1ldihydro-l0,1l-dihydroxy-S-[3-(1-methyl-4- piperazinyl -propylidene] -5H-dibenzo [a,d cycloheptene 10,1 1-dihydro-lO,1 l-dihydroxy-S-(3-dimethylaminopropylidene)-5H-dibenzo[a,d1cycloheptene 10,1 1-dihydro-10,1l-dihydroxy-S-(3-methylaminopropylidene -5H-dibenzo a,d] cycloheptene 3 -chloro-10,11-dihydro-'10,1l-dihydroxy-S-(3-dimethylaminopropylidene) -5H-dibenzo [a,d] cycloheptene 10, 1 1-dihydro-10,1 1-dihydroxy-5-( B-methylaminopropylidene -3 -methylsulfonyl-5H-dibenzo[a,d1cycloheptene 10, 1 l-dihydro-lO, 1 l-dihydroxy-S- 3-dimethylaminopropylidene) -3-trifiuor0methyl-SH-dibenzo [a,d] cycloheptene 10 ,1 1-dihydro-10,1 1-dihydroXy-5-(3-diethylaminopropylidene) -3-dimethylsulfamoyl-5H-dibenzo [a,d1cycloheptene The compounds represented by the above structural formulae can advantageously be employed in pharmaceutical applications because they have been found to possess anti-depressant activity. As anti-depressants, they may be administered orally in the form of tablets, powders, sustained release pellets and the like, or they may be administered orally or parenterally in the form of aqueous solution or suspensions. When administered orally or parenterally, satisfactory results are obtained at a daily dosage level of from about mg. to about 1,000 mg, preferably given in divided doses over the day or in sustained release form. The compounds are preferably administered in the form of their non-toxic acid addition salts and these salts are included within the scope of this invention.
The compounds represented by the above structural formulae exist as geometric isomers, which are determined by the steric relationships of the hydroxyl groups to each other. In order to prepare the separate isomers, it is necessary to employ an appropriate starting material in the same isomeric form as that desired of the end product. Thus, where it is desired to prepare the trans isomer of the compounds represented structurally above, a trans 3a,12 3dihydro-8H dibenzo[3,4:6,7]cyelohepta[1,2 d]- 1,3-dioxol-8-one is employed, whereas the cis isomers are prepared starting with a cis 10,11-dihydro-10,11-diacyloxy- SH-dibenzo[a,d1cyclohepten-5-one.
In carrying out the process, the desired ketone is treated with a Grignard reagent, namely, a tertiary aminopropylmagnesium halide and the Grignard adduct obtained hydrolylzed to form the corresponding S-hydroxy-S-(S- tertiary aminopropyl) derivative. This is then dehydrated to form the corresponding 5-(3-tertiary aminopropylidene) derivative, which is then either hydrolyzed to form the cis or trans 10,11-dihydr0xy compounds represented by structural Formula I or dealkylated and then hydrolyzed to form the cis or trans 10,11-dihydroxy compounds represented by structural Formula II.
The process for the preparation of the trans 10,11- dihydroxy compounds represented by structural Formula I may be illustrated as follows:
RI] RIII C 1. HalMgCHmCHgCHgN\ Hydrolysis Stay A RI! R!!! i i X I I X I-IO CH CIIiCIIzN l Dehydration Stop 13 Hydrolysis X R Step C R l CHCH2CII2N I CHCHzCHzN wherein Hal represents halogen, preferably chlorine or bromine and X, X, R and R are as previously defined; and R" and R are hydrogen, alkyl, aralkyl or aryl.
The starting compound, wherein X and X are both hydrogen and R" and R' are both methyl, namely, the 30:,125 dihydro-2,2-dimethylSH-dibenzo[3,4: 6,7]cyclohepta[1,2-d]-l,3-dioxol-=8-one, may be prepared in the manner described by G. L. Buchanan and D. B. Jhaveri in the J. Org. Chem. 26, 4295-4299 (1961). Those starting compounds, wherein at least one of X and X is other than hydrogen, may be prepared from the corresponding nuclearly substituted H dibenzo[a,d]cyclohepten-5-one utilizing the procedure of G. L. Buchanan and D. B. Jhaveri, referred to above. The latter compounds may be prepared following the teachings of T. W. Campbell et al. in an article appearing in Helv. Chem. Acta, vol. 36, pp. 1489-1499 (1953).
Those starting compounds, wherein R" and R are other than methyl, may be prepared from the corresponding diol by treatment with an appropriate aldehyde or ketone utilizing the procedure described by G. L. Buchanan and D. B. Jhaveri for the preparation of the acetonide of the trans diol appearing in the article referred to above.
It should be noted that inasmuch as the R and R substituents are removed during the preparation of the end compounds of this invention, the selection of the particular starting compound with respect to these substituents Will be dependent only upon their ease of preparation and the removal of the R and R' substituents during subsequent hydrolysis.
The Grignard reagent employed in Step A of the above process may be prepared by known procedures, but it has been found that it may be prepared in high yields as follows:
It has been found that the use of tetrahydrofuran as the solvent for the reaction results in a rapid production of the Grignard reagent in high yield.
The reaction With the Grignard reagent (Step A) is preferably initially carried out under cooled conditions such as by the use of an ice-bath, and finally may continue at room temperature. It has been found that tetrahydrofuran is a suitable solvent for carrying out the reaction and, accordingly, the ketone may be added directly to the reaction mixture in Which the Grignard reagent was prepared. However, any inert solvent for the reactants may be employed.
After the addition reaction is completed, the bulk of the solvent is removed by vacuum distillation, the Grignard adduct dissolved in a suitable solvent such as benzene, and hydrolyzed by the addition of water or ammonium chloride solution with cooling. The product is recovered by evaporation of the solvent after the removal of any residual inorganic material by filtration.
Conversion of the carbinol to the corresponding 5-(3-tertiary aminopropylidene) derivative (Step B) is effected by dehydration. The dehydration may be effected in conventional manner employing such commonly used dehydrating agents as acetyl chloride, acetic anhydride or thionyl chloride. The alcohol may be dehydrated directly or may be first converted to a salt such as the hydrochloride, hydrobromide or sulfate. Conversion to the salt prior to dehydration may be preferable in some cases. The reaction may be carried out at elevated temperatures, and in an excess of dehydrating agent or a solvent such as chloroform or glacial acetic acid may be employed. The desired product is recovered after rendering the mixture alkaline by extraction with a suitable solvent, and then removing the solvent.
Conversion of the compound obtained from Step B to the corresponding trans 10,11-dihydroxy compound (Step C) is effected by hydrolyzing the former in an inert solvent, preferably at elevated temperatures, and in the presence of an acidic catalyst such as, for example, p-toluenesulfonic acid, concentrated sulfuric acid, trifiuoroacetic acid, dry hydrochloric acid and the like. Any number of inert solvents may be utilized, but it is preferred to employ a lower alkanol such as methanol, ethanol, isopropanol and the like. Where the product is insoluble in the solvent employed, it may be recovered by filtration and washed free of any residual acid and further purified by conventional methods. Where the product is soluble in the solvent employed, it may be recovered by evaporation of the solvent, diluting with water, neutralizing any residual acid with sufficient alkali to render the medium basic and collecting the residue by conventional methods.
The trans 10,11-dihydroxy compounds represented by structural formula II may be prepared from the corre sponding 5-(3-dialkylaminopropylidene) compound obtained in Step B above. In carrying out the process, it is preferred that the alkyl substituents attached to the nitrogen atom be the same. This is readily accomplished by appropriate selection of the Grignard reagent used to prepare the carbinol from which the tertiary aminopropylidene compound is derived. This process may be illustrated as follows:
wherein Hal, X, X, R, R and R are as previously defined and R"" is alkyl, aralkyl and aryl. However, it will be readily appreciated by those skilled in the art that inasmuch as the R" substituent is removed during the dealkylation step, the selection of the particular haloformate will be limited only by its availability and subsequent ease of hydrolysis of the intermediate urethane produced.
Step D of the above process involves the condensation of the tertiary amino compound with a haloformate to form the corresponding urethane intermediate. While the reaction can be carried out in the absence of a solvent, it is preferable to employ a solvent. Suitable solvents include the aromatic hydrocarbons such as benzene and toluene aliphatic hydrocarbons such as heptane and hexane, and the halogen hydrocarbons such as chloroform and carbon tetrachloride. The reaction may be carried out at room temperature, although an elevated temperature is preferred. At the conclusion of the reaction, the urethane is recovered, after removal of impurities, by evaporation of the solvent.
The urethane intermediate thus produced is then subjected to hydrolyysis (Step E). The hydrolysis preferably may be carried out under basic conditions. After completion of the hydrolysis, the desired product is recovered in conventional manner, such as by extraction into a suitable solvent and evaporation of the solvent. Conversion to the corresponding 10,1l-dihydroxy compound is accomplished using the procedure outlined in Step C.
Alternatively, the dealkylation may be accomplished by treatment of the tertiary aminop-ropylidene compound with a cyanogen halide to form the corresponding cyanamide intermediate, and the cyanamide thus produced hydrolyzed to the corresponding secondary amine. This process may be illustrated as follows:
iinornommml CHCHgCHzN 0 H O HzCI IzNH Hydrolysis Step 0 The tertiary amine is dissolved in a non-hydroxylic solvent such as benzene or ether and the solution slowly added to a solution of cyanogen halide in the same solvent, while stirring and permitting the alkyl halide to escape. After the reaction is complete, the basic material is separated by Washing with dilute acid and the cyanamide isolated by evaporating the solvent. The cyanamide is hydrolyzed to the secondary amine in an alkaline medium, and the product recovered in conventional manner. Conversion to the corresponding 10,11-dihydroxy compound is accomplished using the procedure outlined in Step C.
The process for the preparation of the cis 10,11--dihydroxy compounds of structural formula I may be illustrated as follows:
A00 OAc HsrM omomomN Hydrolysis Step A AcO 0A0 Dehydration Step B Hydrolysis X R CHCII CII N wherein Hal, X, X, R and R are as previously defined and Ac represents acyl.
The starting compound, wherein X and X are both hydrogen and Ac is acetyl, may be prepared in the manner described by J. Rigaudy and L. Nedelec, Bull. Soc. Chim., France (1960), pgs. 400-405. Those starting compounds, wherein at least one of X and X is other than hydrogen, may be prepared from the corresponding nuclearly substituted SH-dibenzo[a,d]cyclohepten-5- one utilizing the procedure of J. Rigaudy et a1. previously mentioned. Those starting compounds, wherein Ac is other than acetyl, may be prepared from the corresponding diol by treatment with an appropriate acylating agent following the procedure described by J. Rigaudy et al., above cited, for the preparation of the 10,11-di'acetoxy derivative.
The preparation of the Grignard reagent, the reaction with the Grignard reagent (Step A), and dehydration of the resulting carbinol (Step B), may be carried out as previously described herein. However, the hydrolysis of the 10,11-diacyloxy compound to the corresponding cis 10,11-dihydroxy compound differs from that described for the preparation of the trans 10,11- dihydroxy compounds in that the hydrolysis is effected under alkaline conditions such as by the use of potassium hydroxide and the like. Recovery of the product can be accomplished as described in Step C above, except that neutralization with alkali is unnecessary.
An alternate method for the preparation of the cis 10,11-dihydroxy compounds represented by structural Formula I may be illustrated as follows:
1. Osmium tetroxide 2. Hydrolysis CIIGI-IzCHzN X i l R UHCI-HCH N This process involves treating a -(3-tertiary aminopropylidene) 5H dibenzo[a,d]cycloheptene with an equimolar amount of osmium tetroxide and then hydrolyzing the resulting osmic ester. The reaction with the tetroxide is preferably carried out at room temperature and in a dry, inert solvent in which the osmium tetroxide is soluble. A particularly suitable solvent is dry benzene. Preferably, a catalyst is employed to facilitate the reaction, and pyridine is suitable for this purpose. After completion of the reaction, which may take several days or more, the osmic ester which precipitates out may be recovered by filtration. Hydrolysis of the ester to the desired product is conveniently efifected in an aqueous, inert organic solvent such as an aqueous alkanol, preferably ethanol. The hydrolysis is preferably carried out at reflux temperature and in the presence of a suitable reducing agent such as sodium sulfite. The reducing agent is employed for the purpose of recovering the osmium which precipitates out in metallic form. After removal of the metallic osmium by filtration, the product is readily recovered in conventional manner.
The 5 (3-tertiary aminopropylidene)-5H-dibenzo[a,d] cycloheptene employed in the process may be readily obtained by treating the appropriately substituted 5H- dibenzo[a,d]cycloheptn-S-one with a Grignard reagent, namely, tertiary aminopropyl magnesium halide, hydrolyzing the resulting Grignard adduct to form the corresponding carbinol and dehydrating the latter, as described in the literature.
The preparation of the cis 10,11-dihydroxy compounds represented by structural Formula II may be accomplished by dealkylating the corresponding cis 10,11 diacyloxy-5-(3-dialkyylaminopropylidene) derivative in the same manner as described for the dealkylation of the trans 5-(3-dialkylaminopropylidene) derivative, as described in Steps D and E above. This process may be illustrated as follows:
A00 ()Ac l-Ialotormate llalCOOR Step D Hydrolysis atop E HO OH C HCHzCHzNHR wherein Ac, Hal, R, R"", X and X are as previously defined.
It should be noted that the alternate method of dealkylation mentioned hereinabove for the preparation of the trans 10,11-dihydroxy compounds of structural Formula II cannot be used for the preparation of the cis 10,11-dihydroxy compounds of Formula II.
It will be readily appreciated by those skilled in the art that the compounds represented by Structure I and II, in addition to the element of geometric isomerism determined by the relationship of the hydroxyls to each other, possess a second element of geometric isomerism when the dibenzocycloheptene nucleus is unsymmetrically substituted, depending on the position of the propylidene side chain relative to the nuclear substituent(s).
The separation of these isomers can be achieved by conventional techniques. While the mixture of such isomers possess pharmacological activity, in some instances thc activity may be greater in one pure isomer than the other.
Inasmuch as the compounds of this invention may exist as geometric isomers with respect to the hydroxyl substituents only or with respect to both the hydroxyl substituouts and the propylidene side chain, the following procedure for desigating the isomers hereinabove and in the examples and claims which follow has been employed. Where isomers exist only with respect to the hydroxyl substituents, the designation of the particular isomer precedes the name of the compound. Where isomers exist as to both the hydroxyl substituents and the propylidene side chain, the designation of the isomers immediately precedes the substituent to which it refers. In those instances where isomers exist with respect to both the hydroxyl substituents and the propylidene side chain and the isomers of the latter have not been separated, then only the designation of the isomer with respect to the hydroxyl substituents is given and such designation precedes the name of the compound. However, where no designation of isomers is specified with respect to the compounds of this invention, it is to be understood that all possible stereoisomers are included.
The preparation of representative compounds encompassed within the scope of the present invention is described in the following examples which are illustrative only and are not to be construed as in any way limiting the scope of the invention.
EXAMPLE 1 Trans 3 :,125- dihydro-2,2-dimethyl-8- 3-dimethylaminopropyl)-8-hydroxy-8H-dibenzo[3,4:6,7]cyclohepta[1,2- d] -l,3-dioxole 3-dimethylaminopropylmagnesium chloride is prepared from magnesium turnings (4.05 g., 0.166 g. atom) and B-dimethylaminopropyl chloride (20.2 g., 0.166 mole) in 150 ml. of dry tetrahydrofuran, following the method of U.S. Patent No. 3,046,283. In a nitrogen atmosphere, a solution of trans 3oz,12p-dihydro-2,2-dimethyl-8H-dibenzo- [3,4:6,7]cyclohepta[1,2-d] 1,3 dioxol 8 one (23.2 g., 0.083 mole) in 100 m1. of dry tetrahydrofuran is added dropwise to the stirred solution of the Grignard reagent while cooling in an ice-bath. The mixture is allowed to come to room temperature and stirred for 2 hours. The bulk of the solvent then is distilled below 50 C. under reduced pressure. The residue is dissolved in 150 ml. of benzene and water, 20 ml., is added dropwise with stirring and cooling. The benzene layer is decanted from the gelatinous precipitate which then is extracted with four 100 ml. portions of boiling benzene. The combined benzene extracts are washed with water and extracted with three 100 ml. portions of 0.5 M citric acid. The acid extract is made basic with sodium hydroxide, and the oily base that separates is extracted into benzene. After washing the combined extracts with water and drying over anhydrous sodium sulfate, the benzene is evaporated and the product obtained as a viscous yellow oil in a yield of 29.5 g. (96% The base may be converted to the hydrogen oxalate salt by treating an ethereal solution with a solution of oxalic acid excess) in isopropyl alcohol. The trans 3a,12,8-dihydro-2,2-dimethyl8-(3-dimethylaminopropyl)- 8 hydroxy-SH-dibenzo[3,4:6,7]cyclohepta[1,2-d]-1,3-dioxole hydrogen oxalate is obtained as a white crystalline solid, M.P. 169-172 C., dec. Repeated recrystallizations from mixtures of isopropyl alcohol and absolute ether give the product, M .P. 171-173 C., dec.
Analysis.Calcd for C H NO 'C H O C, 65.62; H, 6.83. Found: C, 65.08;H, 6.72.
EXAMPLE 2 Following the procedure of Example 1, the products enumerated below are obtained using the ketone of Example l and the Grignard reagent designated below.
3diethy1aminopropylmagnesium chloride.
3-(1-pyrro1idyl)-propylmagnesium chloride.
3-(1-piperidy1)-propylmagnesium chloride.
3-(1-ethyl-4-piperazinyl) propylmagnesium chloride.
3-(4-m0rpholinyl)-propylmagnesium chloride.
S-(N-etliyl-N-methylsmino)- propyhnagnesium chloride.
EXAMPLE 3 Ketone Product trans 311,126-dihy(lro-2,2-di1nethylti-rnethylsulionyl-SH-dlhenzo [3,4:6,7]cyelohepta[1,2-d]-1,3- (lioxol-8one.
EXAMPLE 4 Trans 305,125 dihydro-2,2-dimethyl-8-(E-dimethylaminopropylidene) 8H dibenzo[3,4:6,7]cyclohepta[ 1,2-d]- 1,3-dioxole A solution of trans 3a,lZB-dihydro-Z,2-dimethyl-8-(3- dimethylaminopropyl) 8 hydroxy-8H-dlibenzo[3,4:6,7] cyclohepta[1,2-d]-l,3-dioxole (1.3 g., 0.00354 mole) in 15 ml. of acetic anhydride is heated to refluxing for 4 hours. The solution is evaporated to dryness under reduced pressure and the residual syrup dissolved in 30 ml. of water. After one extraction with hexane, the aqueous layer is rendered alkaline with sodium hydroxide and the oily base extracted into benzene. The washed benzene extract is evaporated under reduced pressure, leaving the product as an oily residue weighing, typically, 950 mg. Treatment of an ethereal solution of the base with a solution of 300 mg. of oxalic acid in 3 ml. of isopropyl alcohol precipitates trans 3a,l2B-dihydro 2,2 dimethyl-S-(E-dimethylaminopropylidene)-8H-dibenzo[3,4:6,7]cyclohepta[1,2 d]-l,3- dioxole hydrogen oxalate, M.P. 204206 C., dec., in a yield of 1.05 g. (67.5%). The pure product from another EXAMPLE 5 Following the procedure of Example 4, the products enumerated below are obtained employing the products enumerated in Examples 2 and 3 in place of the dioxole used in Example 4.
Trans 8-(3-diethylaminopropylidene)-3tt,l2fi-dihydro-2,2- dimethyl-SH-dibenzo[3,4:6,7)cyclohepta[1,2-d]-1,3-dioxole trans 30,1ZB-dihydro-Z,Z-dimethyl-S-[3-( l-pyrrolidyl)- propylidene]-8Hdibenzo[3,4 6,7] cyclohepta[ 1,2-d1- 1,3-dioxole trans 3a,12-dihydro-Z,2-dirnethy1-8-[3-(l-ethyl-4-piperainyl) propylidene] -8H-dibenzo[3,4 6,7] cycloheptal l, 2-d]-l,3-dioxole trans 3a,125-dihydro-2,2-dimethyl-8-[3-(4-morpholinyl)- propylidene1-8H-dibenzo [3,4 6,7] cyclohepta 1,2-d] 1,3-dioxole trans 3a,12,8-dihydro-2,2-dimethyl-8-[3-(N-ethyl-N-methylamino)-propylidene]-8H-dibenzo[3,4:6,7]cyclohepta- [1,2-d]-1,3-dioxole trans 3a,12,8-dihydro-8-(3-dimethylaminopropylidene)- 8H-dibenzo[3,4:6,7]cyclohepta[1,2-d]-1,3-dioxole trans 3a,12,B-dihydro-8-(3-dimethylaminopropylidene)-2- phenyl-8H-dibenzo[3,4:6,7]cyclohepta[l,2,d]-1,3-dioxole trans 3a,12,8-dihydro-8-(3-dimethylaminopropylidene)-2- methyl-SH-dibenzo 3,4: 6,7] cyclohepta[ 1,2-d] -1,3-dioxole trans 2-benzyl-3 a,l2,8-dihydro-8-(3-dimethylaminopropylidene)-8H-dibenzo[3,4 6,7] cyclohepta[ 1,2-d]-1,3- dioxole trans 3a,12fi-dihydro-8-(3-dimethylaminopropylidene)- 2-ethyl-Z-methyl-SH-dibenzo[3,4:6,7]cyclohepta[1,2- d] -1,3 -dioxole trans 3a,lZ -dihydr-2,2-dimethyl-8-(3-dimethylaminopropylidene)-6-methylsulfonyl-SH-dibenzo[3,426,71- cyclohepta[1,2-d]-1,3-dioxole trans 6-chloro-3ot,125-dihydro-2,2dimethyl-8-(3-dimethylaminopropylidene)-8H-dibenzo [3,4 6,7] cyclohepta- [1,2-d]-1,3-dioxole trans 3a,l2fi-dihydro-2,2-dimethyl-8-(3-dimethylaminopropylidene)-6-dimethylsulfamoyl-8H-dibenzo[3,4 :6, 7]-cyclohepta[1,2-d]-1,3-dioxole.
EXAMPLE 6 trans 10,1 1-dihydro-10,l l-dihydroxy-S-(3-dimethylaminopropylidene)-H-dibenzo[a,d]cycloheptene A solution of trans 3a,1ZE-dihydro-Z,2-dimethyl-8-(3- dimethylaminopropylidene) 8H dibenzo[3,4:6,7]cyclohepta[1,2-dJ-1,3-dioxole (350 mg, 0.001 mole) and ptoluenesulfonic acid monohydrate (230 mg. 0.0012 mole) in 35 ml. of absolute methanol is heated to refluxing for 4 hours. The cooled solution is neutralized with 1 ml. of l M potassium hydroxide in methanol and then the solvent is distilled under reduced pressure. The residue is partitioned between benzene and water and the aqueous layer rte-extracted twice with benzene. The combined benzene extracts are washed with water and then evaporated to dryness under reduced pressure. Trituration of the residue with absolute ether yields the product as a white crystal line solid, MP. l32.5134.5C., weighing 230 mg. (74.5%). After purification by sublimation and crystallization from a mixture of ethanol and water, an analytical sample melts at 134.5136.5 C.
Am1Iysz's.- Calcd for C H NO C 77.64; H, 7.49; N, 4.53. Found: C, 77.59; H, 7.42; N, 4.47.
12 EXAMPLE 7 Following the procedure of Example 6, the products enumerated below are obtained using the products enumerated in Example 5 in place of the dioxole used in Example 6.
trans 5-(3-diethylaminopropylidene-10,1l-dihydro- 10, ll-
dihydroxy-SI-I-dibenzo [21,] cycloheptene trans 10,11-dihydro-10,11-dihydroxy-5-[3-(1-pyrrolidyl)- propylidene] -5H-clibenzo [a,d] cycloheptene trans 10,11-dihydro-10,l1-dihydroxy-5-[3-(l-pipcridyl) propylidene]-5H-dibenzo[a,d]cycloheptene trans 10,11-dihydro-10,11-dihydroxy-5-[3-(1-ethyl-4- piperazinyl -propylid ene] -5H-dibenzo [a,d cycloheptene trans 10,11-dihydro-10,11-dihydroxy-5-[3 (4- morpholinyl)propylidene]-5H-dibenzo[a,d]cycloheptene trans 10,1l-dihydro-10,1l-dihydroxy-S-[3-(N-ethyl N- methylamoino)-propylidene] 5H-dibenzo[a,d] cycloheptene trans 10,1 1-dihydro-10,11-dihydroxy-5-(3-dimethylamino propylidene)-5 H-dibenzo [a,d]cycloheptene trans 10,11-dihydro-10,11-dihydroxy-5-(Z-dimethylamino propylidene)-3-methylsulfonyl-SH-dibenzo[a,d] cycloheptene trans 3-chloro-10-1l-dihydro-lO-l l-dihydroxy-5-(3 dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene trans 10,11-dihydro-10,11-dihydroxy-5(3-dimethylaminopropylidene)-3-dimethylsulfamoyl-5H-dibenzo[a,d] cycloheptene EXAMPLE 8 trans 8-[3-(N-cyano-N-rnethylarnino)-propylidiene] c,
12p-dihydr02,2-dimethyl 8H-diben2o[3,4:6,7] cylohepta[1,2-d]-1,3-dioxole In a system protected by a drying tube, and in which a nitrogen atmosphere is maintained, a solution of trans 3a,1Zfi-dihydro-2,2-dimethyl-8 (3 dimethylaminopropylidene)-8H-dibenzo[3,4:6,7]cyclohepta[1,2-d]-1,3 dioxole (2.25 g., 0.00645 mole) in 12 ml. of dry benzene is added dropwise over a 30 minute period to a stirred solution (1.85 ml.) of 4.25 M cyanogen bromide in benzene. Stirring is continued for 1 /2 hours and the mixture then allowed to stand at room temperature overnight. Solvent and excess cyanogen bromide are evaported under reduced pressure and the residue dissolved in benzene. The solution is washed with water, dilute citric acid, then with water, and evaporated to dryness under reduced pressure. The trans 8-[3-(N-cyano-N-methylamino)-propylidene] 304,12/3 dihydro-2,2-dimethyl-8H dibenzo [3,426,7]cyclohepta[1,2-d]-1,3-dioxole is obtained as a yellow oily residue, weighing 1.8 g. (78%).
EXAMPLE 9 Following the procedure of Example 8, the products enumerated below are obtained employing the 8-(3-dialkylaminopropylidene) products enumerated in Example 5 in place of the dioxole used in Example 8.
trans 8-[3-(N-cyano-N-ethylamino)-propylidene]-3ot,
1ZB-dihydro-2,2-dimethyl-8H-dibenzo[3,4:6,7]cyclohepta[1,2-d]-1,3-dioxole trans 8-[3-(N-cyano-N-rnethylamino)-propylidene]-3u, 12fi-dihydro-8H-dibenzo[3,416,7]cyclohepta[1,2-d] 1,3-dioxole trans 8"[3-(N-cyano-Nmethylamino)-propylidene]-3ot,
1ZB-dihydro-Z-phenyl-8Hdibenzo[3,4:6,7] cyclohepta [1,2-4]-1,3-dioxole trans 8-[3-(N-cyano-N-methylamino)-propylidene]-3a,
1ZQ-dihydro-Z-methyl-SH-dibenzo[3,4:6,7] cyclohepta [1,2-d]-1,3-dioxole trans 8- 3- (N-cyano-N-methylamino -propylidene] -3a, 1ZB-dihydro-Z-ethyl-Z-methyl-SH-dibenzo 3,4: 6,7] cyclohepta- 1,2-d] -1,3-dioxole trans 8- 3-(N-cyan0-N-methylamino -propylidene] -3u,
12/3-dihydro-2,2-dimethyl-6-methylsu1fonyl-SH-dibenzo [3,4:6,7]cyclohepta[1,2-d]-l,3-dioxole trans 6-chloro-8- 3-(N-cyano-N-methyla mino)-propylidene] 3ot,12,B-dihydro-2,2-dimethyl-SH-dibenzo [3,426, 7] cyclohepta[ 1,2-d] -1,3-dioxole trans 8- 3- (N-cyano-N-methylamino -propy1idene] -3u, 1ZB-dihydro-2,2-dimethyl-6-dimethylsulfamoyl-8 l-Ldibenzo-[3,4:6,7]cyclohepta[1,2-d]-1,3 -dioxole EXAMPLE 10 Trans 30,l25 dihydro 2,2 dimethyl 8 (3 methylaminopropylidene) 8H dibenzo[3,4:6,7]cyclohepta- [1,2-d] -1,3-dioxole The oily cyanamide (1.44 g., 0.004 mole), prepared as in Example 8 above, .is dissolved in a solution of potassium hydroxide (1.12 g., 0.02 mole) in 12 ml. of nbutyl alcohol and the solution is heated to refluxing in a nitrogen atmosphere for 12 hours. The solvent is distilled under reduced pressure and the residue partitioned between hexane and water. After two re-extractions of the aqueous layer with hexane, the combined hexane extracts are washed with water and extracted with 50 ml. of 0.1 M citric acid. The acid extract is rendered alkaline with sodium hydroxide and the oily base extracted into benzene. The washed and dried benzene extract is evaporated to dryness under reduced pressure, leaving the product as an oily residue weighing, typically, 920 mg.
The base may be converted to the hydrogen oxalate salt by treating an ethanolic solution with a solution of oxalic acid (10% excess) in absolute ethanol. Analytically pure trans 3a,12B-dihydro-2,2-dimethyl-8-(3-methylaminopropylidene) 8H dibenzo[3,4:6,7]cyclohepta[1, 2d]-1,3-dioxole hydrogen oxalate from another experiment melts at 224 C., dec., after repeated recrystallizations from absolute ethanol.
Analysis.Calcd for C22H25NO2'C2H204: C, H, 6.40; N, 3.29. Found: C, 67.78; H, 6.32; N, 3.41.
Conversion of the oily base (900 mg.) to the p-toluenesulfonate salt by treating an ethereal solution with a solution of p-toluene sulfonic acid monohydrate (5% excess) in absolute ethanol, aifords the white crystalline salt, MP.
148150 C., dec., in a yield of 950 mg.
EXAMPLE 11 Following the procedure of Example 10, the products enumerated below are obtained employing the products enumerated in Example 9 in place of the cyanamide used in Example 10.
trans 3 a,1ZB-dihydro-2,2-dimethyl-8-=(3-ethylaminopropylidene)-8H-dibenzo[3,4:6,7]cyclohepta[1,2-d]-1,3- dioxole trans 3 u,12B-dihydro-8- 3 -methylaminopropylidene SH-dibenzo [3 ,4: 6,7] cyclohepta[ 1,2-d] -1,3-dioxole trans 3 a,l2l3 dihydro-8-(3-methy1aminopropylidene)-2- phenyl-8H-dibenzo[3,4:6,7]cyclohepta[1,2-d]-1,3- dioxole trans 3 a, 1 2,9-dihydro-2-methyl-8- 3-methylaminopropylidene)-8H-dibenzo[3,4:6,7]cyclohepta[1,2-d] 1,3- dioxole trans 2-benzyl-3 a,12B-dihydro-8-(3-methylaminopropylidene)-8H-dibenzo[3,4:6,7]cyclohepta[1,2-d]-1,3- dioxole trans 3 a,12,8-dihydro-Z-ethyl-Z-methyl-S-(3-methylaminopro pylidene -8H-dibenzo[ 3 ,4: 6,7 cyclohepta[ 1,2-d] 1,3-dioxole trans 3a,12/3-dihydro-2,2-dimethyl-8-(3-methylaminopropylidene) -6-methylsulfonyl-8H-dibenzo 3,4 6,7] cyclohepta[ 1,2-d] -1,3-dioxole trans 6-chloro-3 a,1ZB-dihydro-Z,2-dimethyl-8-(3 -methyll 4 aminopropylidene) -8H-dibenzo[3,4: 6,7]cyclohepta[ 1, 2 d] -1,3-dioxole trans 3a,12fi-dihydro-2,2-dimethyl-6-dimethylsulfarnoyl' 8-(3-methylaminopropylidene) -8H-dibenzo [3,4 6,7] cyclohepta[1,2-d] 1,3-dioxole EXAMPLE 12 Trans 10,11 dihydro 10,11 dihydroxy 5 (3-methylaminopropylidene -5H-dibenzo[ a,b] cycloheptene A solution of trans 3a,12/8-clihydro-2,2-dimethyl-8-(3- methylaminopropylidene) 8H dibenzo[3,4:6,7]cyclohepta[l,2-d]-l,3-dioxole p-toluenesulfonate (700 mg., 0.00138 mole) and p-toluenesulfonic acid monohydrate (60 mg., 0.000316 mole) in 60 ml. of absolute methanol is heated to refluxing for 4 hours. The cooled solution is neutralized with 1.5 ml. of l M potassium hydroxide in methanol and then the Solvent is distilled under reduced pressure. The residue is partitioned between benzene and and water and the aqueous layer re-extracted with benzene. The combined benzene extracts are washed with Water and then evaporated to dryness under reduced pressure, leaving the product as an oily solid residue. Sublimation of the product at 142 C. and 0.1 mm. affords white crystals, M.P. 153-155 C., weighing, typically, 120 mg. (30%). An analytical sample is obtained. by crystallization from a mixture of ethanol and water and resublimation, and melts at 154156 C.
Analysin-Calcd for C H NO C, 77.26; H, 7.17; N, 4.74. Found: C, 77.48; H, 7.12; N, 4.77.
EXAMPLE 13 Following the procedure of Example 1.2, the products enumerated below are obtained employing the products enumerated in Example 11 in place of the dioxole used in Example 12.
trans 10,1l-dihydro-10,l l-dihydroxy-5-(3-ethylaminopropylidene -5H-dibenzo a,d]cycloheptene trans 10,1 l-dihydrol 0,1 l-dihydroxy-S- 3 -.methylarninopropylidene -51- -dibenzo a,d] cycloheptene trans 10,11-dihydro-l0,11-dihydr0xy-5-(B-methylaminopropylidene) -3-methylsulfonyl-SH-dibenzo [a,d] cycloheptene trans 3-chloro- 1 0,1 l-dihydro- 1 0, l l-dihydroxy-S- 3- methylaminopropylidene -5H-dibenzo [a,d] cycloheptene trans 10,11-dihydro-l0,1 l-dihydroxy-3-dimethylsulfamoyl-5- 3-methylaminopr0pylidene -5H-clibenzo [a,d] cycloheptene EXAMPLE 14 Cis 10,1l-diacetoxy-10,1l-dihydro-5-(3 -dimethylaminopropyl -5-hydroxy-5H-dibenzo [a,d]cycloheptene 3-dimethylaminopropylmagnesium chloride is prepared from magnesium turnings (4.86 g., 0.2 g. atom) and 3- dimethylaminopropyl chloride (24.3 g., 0.2 mole) in ml. of dry tetrahydrofuran following the method of US. Patent No. 3,046,283. In a nitrogen atmosphere, the solution of the Grignard reagent is added. dropwise to a stirred suspension of cis 10,11-diacetoxy-10,1l-dihydro- SI-I-dibenzo[a,d]cyclohepten-5-one (30.0 g., 0.0925 mole) in 60 ml. of tetrahydrofuran while cooling in an ice-bath. The mixture is stirred in the cold for 2 hours and the bulk of the solvent then is distilled below 50 C. under reduced pressure. The residue is dissolved in benzene and Water, 30 ml., is added with stirring and cooling. The benzene is decanted and the gelatinous precipitate washed by decantation with boiling benzene. The combined benzene extracts are extracted repeatedly with 0.5 M citric acid. The acid extract is rendered alkaline with sodium hydroxide and the oily base extracted into benzene. Evaporation of the washed and dried benzene extract: under reduced pressure leaves a yellow glass which is extracted into 1 l. of cyclohexane. The solution is filtered from insoluble material and the solvent evaporated. Crystallization of the o o mp EXAMPLE 15 Following the procedure of Example 14-, the products enumerated below are obtained employing the ketone of Example 14 and the Grignard reagent designated below.
Product Grignard reagent 3-diethylaminopropyhnagmagnesium chloride.
E-(I-pyrrolidyl)-propylmagnosiuni chloride.
3 (1pipcridyl)-propylmagnesium chloride.
3-(Lothyl-4-pipcrazinyl)- propylmagncsiuin chloride.
3-(4-ruorpholinyl)-propylmagnesium chloride.
3-(N-ethyl-N-methylamino)- propyhnagncsium chloride. [3-(N-cthyl-N-mcthylan1ino)- propyl]-5-hydroxy-5H-diheuzo [a,rl1cycloheptenc.
EXAMPLE 16 Following the procedure of Example 14, the products enumerated below are obtained employing the Grignard reagent of Example 14 and the ketone designated below.
Ketone Prod] ict cis 10,11-(libutyryloxy-10,1ldihydro-5H-dibenzo-[o,d] cyciohepten-S-one.
cis 3-chloro-10,11-di-aeet0xy-10,1l-
dihydro-5H-dibenzo[a,d]- cycloheptene-one.
cis 10,11-rlihydro-5-(3 dimethylaminopropyl)-10,- ll-clipropionyloxy-E-hydroxy- 5ll-dibenzo[a,dl-cycloheptcnc.
cis 10,11-dibutyryloxy- 10,11-
dihydro-o-(3-dimothylaniinopropyl)-5-hydroxy-SH-dibenzo [a,d]-cycloheptene.
cis l0,ll-dicaproyloxy-l0,ll-
(lihydro-5-(3dimethylaminopropyl)-5'hydroxy-Slhdibcnzola,d]cyelohcpteue.
cis 3-chloro-l0,1l-di-acetoxy-lOJL dihydro-o-(B-dimcthylaminopropyD-S-hydroxy-EH-dibcnzo- [a,dleycloheptenc.
cis 10,11diacotoxy-10,ll-diliydro- 5-(3di-methylaminopropyD- 5hydroxy-B-methylsulfonvlcis 10,11-diacetoxy-10,ll-dihydro- B-dimethylsullamoyl-5l-I-dibenzo- [a,dlcyclohepten-E-one.
EXAMPLE 17 Cis 10,11-diacetoxy-10,11-dihydro-5-(3-dimethy1aminopropylidene) -5Hdibenzo [a,d] cycloheptene A solution of cis 10,11-diacetoxy-10,11-dihydro-5-(3- dimethylaminopropyl) 5 hydroxy 5H dibenzo[a,d] cycloheptene (19.5 g., 0.0475 mole) in 300 ml. of acetic anhydride is heated to refluxing for 4 hours. The solution is evaporated to dryness under reduced pressure and the residual oil partitioned between 0.5 M citric acid and benzene. After repeated washing with benzene, the aqueous acid layer is rendered alkaline with sodium hydroxide and the oily base extracted into benzene. Evaporation of the washed and dried benzene extract leaves the product as an oily residue weighing, typically, 18.0 g. (96.5%).
The base may be converted to the hydrogen oxalate salt by treating an ethanolic solution with a solution of oxalic acid (10% excess) in absolute ether. Cis 10,11-diacetoxy- 10,11 dihydro 5-(3-dimethylaminopropylidene)-5H-dibenz[a,d]cycloheptene hydrogen oxalate precipitates as a white crystalline solid which melts at 165-166" C. after one recrystallization from a mixture of absolute ethanol and absolute ether.
Analysis.Calcd for C24H27NO4C2H2O4: C, H, 6.05; N, 2.90. Found: C, 64.31; H, 5.84; N, 2.79.
EXAMPLE 18 Following the procedure of Example 17, the products enumerated below are obtained employing the products enumerated in Examples 15 and 16 in place of the dibenz ocycloheptene used in Example 17.
cis 10,11-diacetoxy--(3-diethylamin0propylidene)-10,11-
dihydro-SH-dibenzo [a,d, cycloheptene cis 10,11-diacetoxy-10,11dihydro-5-[3-(1-pyrrolidyl)propylidene] -5H-dibenzo [a,d, cycloheptene cis 10,11-diacetoxy-10,1l-dihydro-S-[3-(1-piperidyl)propylidene] -5H-dibenzo a,d] cycloheptene cis 10,11-diacetoxy-10,11-dihydro-5-[3-(1-ethyl-4-piperazinyl -propylidene] -5H-dibenzo [a,d] cycloheptene cis 10,11-diacetoxy-10,1l-dihydro-S-[3-(4-morpholinyl)- propylidene -5H-dibenz0 [a,d] cycloheptene cis 10,11-diacetoxy-10,1 1-dihydro-5-[3-( N-ethyl-N- methylamino propylidene 1 -5I-l-dibenzo [a,d] cycloheptene cis 10,1l-dihydro-S-(3-dimethylaminopropylidene)-10, 1 1-dipropionyloxy-5H-dibenzo [a,d] cycloheptene cis 10,1l-dibutyryloxy-IO,11-dihydro-5-(3-dimethylaminopropylidene) -5H-dibenzo [a,d] cycloheptene cis 10,11-dibenzoyloxy-10,11-dihydro-5-(3-dimethylaminopropylidene -5H-dibeuzo [a,d] cycloheptene cis 10,11-dicaproyloxy-10,1 l-dihydro-S-(3-dimethy1- aminopropylidene) -5H-dibenzo [a,d] cycloheptene cis 3-chloro-10,l1-diacetoxy-10,11-dihydro-5-(3-dirnethylaminopropylidene -5H-dibenzo [a,d] cycloheptene cis 10,1 l-diacetoxy-lO,l1-dihydro-5-(3-dimethylaminopropylidene) -3-methylsulfonyl-5H-dibenzo [a,d] cycloheptene cis ',11-diacetoxy-10,1 l-dihydro-S- 3-dimethylaminopropylidene) -3-dimethylsulfamoyl-SH-dibenzo [a,d] cycloheptene EXAMPLE 19 Cis 10,11 dihydro-10,11-dihydroxy-5-(3-dimethylaminopropylidene -5H-dibenz0 a,d] cycloheptene A solution of cis 10,11-diacetoxy-10,11-dihydro-5-(3- dimethylaminopropylidene) 5H dibenzo[a,d]cycl0- heptene (1.6 g., 0.00417 mole) and potassium hydroxide (1.6 g., 0.024 mole) in 70 ml. of absolute methanol is heated to refluxing for minutes. The solvent is evaporated under reduced pressure and the residue treated with mil. of water. The precipitate is collected, washed with water, and recrystallized from a mixture of ethanol and water to obtain the product as a white crystalline solid, M.P. 173175 C., Weighing 1.05 g. (81%). A purified sample from another experiment melts at 171-174 C. after sublimation at C. and 0.05 mm.
Analysis.Calcd for C H NO C, 77.64; H, 7.49; N, 4.53. Found: C, 77,64; H, 7.50; N, 4.53.
EXAMPLE 20 Following the procedure of Example 19, the products enumerated below are obtained employing the products enumerated in Example 18 in place of the dibenzocycloheptene used in Example 19.
cis 5-(3-diethylaminopropylidene)-10,11-dihydro-10,11-
dihyclroxy-5H--clibenzo [a,d] cycloheptene cis 10,11-dihydro-l0,11-dihydroxy-5-[3-(1-pyrrolidyl)- pro pylidene -5 H-dibenzo [a,d] cycloheptene cis 10,11-dihydro-10,11-dihydroxy-5[3-(1piperidy1)propylidene] -5H-dibenzo [a,d] cycloheptene cis 10,11-dihydro-l0,1l-dihydroxy-5-[3-(1-ethyl-4- 0.04 mole) in 25 ml. of n-butyl alcohol is stirred and heated to refluxing in a nitrogen atmosphere for 6 hours. The solvent is distilled under reduced pressure and the residue partitioned between benzene and water. After reextraction of the aqueous phase, the combined benzene extracts are washed with water and then extracted with 15 ml. and 10 ml. portions of 0.5 M citric acid. The acid extract is rendered alkaline with sodium hydroxide and the oily base extracted into benzene. The washed and dried benzene extract is concentrated to a small volume. The product separates as a white crystalline solid and is collected, washed with benzene, and dried to obtain 1.05 g. (47% M.P. 140-143 C. The pure product from another experiment melts at 143-145 C. after repeated crystallizations from benzene and from mixtures of ethanol and water.
Analysis.Calcd for C H NO C, 77.26; H, 7.17; N, 4.74. Found C, 77.34; H, 7.18; N, 4.59.
EXAMPLE 27 Following the procedure of Example 26, the products enumerated below are obtained employing the products enumerated in Examples 22 and 23 in place of the urethane used in Example 26.
cis 10,11-dihydro-10,1 1-dihydroxy-5-(3-ethylaminopropylidene -H-dibenzo [a,d] cycloheptene cis 10,1 1-dihydro-10,1 l-dihydroxy-S-(3-methy1aminopropylidene) -5H-dibenzo [a,d] cycloheptene cis 3-chloro-10,11-dihydro-10,11-dihydroxy-5-(3- methylaminopropylidene -5H-dibenzo a,d] cycloheptene cis 10,11-dihydro-10,11-dihydroxy-5-(3 -methylaminopropylidene) -3-methylsulfonyl-5H-dibenzo a,d] cycloheptene cis 10, 1 1-dihydro-10,1 1-dihydroxy-3-dimethy1su1- famoyl-S- 3-methylaminopropylidene -5H-dibenzo[ a,d] cycloheptene EXAMPLE 28 Following the procedure of Example 26, the products enumerated below are obtained employing the products enumerated in Examples 24 and 25 in place of the urethane used in Example 26.
trans 10,11-dihydro-10,1l-dihydroxy-S-(3-ethylaminopropylidene -5H-dibenzo [a,d] cycloheptene trans 10,1 l-dihydro-l 0,1 l-dihydroxy-S- 3 -methylamiuopropylidene -5H-dibenzo a,d] cycloheptene trans 3-cl1loro-10,11-dihydro-10,1 1-dihydroxy-5-(3- methylaminopropylidene) -5H-dibenzo a,d] cycloheptene trans 10,1 1-dihydro-10,1 1-dihydroxy-5-(S-methylaminopropylidene) -3 -methylsulfonyl-5H-dibenzo [a,d] cycloheptene transs 10,1 1-dihydro-10,1 1-dihydroxy-3-dimethylsulfamoyl-S- 3-methylaminopropylidene) -5H-dibenzo [a,d] cycloheptene EXAMPLE 29 Cis 10,11 dihydro10,11-dihydroxy-5-( 3-dimethy1amin0- propylidene -5H-dibenzo [a,d] cycloheptene A solution of 5-(3-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene (1.06 g., 0.00386 mole) in 7 ml. of dry benzene and 0.6 ml. of dry pyridine is treated with a solution of osmium tetroxide (1.0 g., 0.00394 mole) in 6 ml. of dry benzene and the mixture allowed to stand at room temperature for days. The solution is decanted from the black precipitate which separates and the solid washed once with 25 ml. of benzene by decantation. The benzene solution and washings are filtered through diatomaceous earth. The combined precipitate and diatomaceous earth are suspended in 60 ml. of 95% ethanol and heated to refluxing for 45 minutes with 25 ml. of a saturated aqueous solution of sodium sulfite. After filtering the mixture through diatomaceous earth, the filtrate is evaporated under reduced pressure until a dark oil separates. The residue is diluted with an equal volume of water and the oily base extracted into benzene. Evaporation of the washed and dried benzene extract leaves the product as an oily solid residue weighing 450 mg. Purification by sublimation at C. and 0.1 mm. and crystallization of the sublimate from a mixture of ethanol and water affords the product as a white crystalline solid, M.P. 172.5175.5 C., in a yield of 250mg. (20%).
Analysis.Calcd for C H O N: C, 77.64; H, 7.49. Found: C, 77.41; H, 7.49.
We claim:
1. A compound selected from the group consisting of compounds having the structural formula HO OH CHCHzCHgN and the non-toxic salts thereof; wherein R and R are selected from the group consisting of lower alkyl radicals and lower alkyl radicals linked together through an atom selected from the group consisting of carbon, nitrogen and oxygen to form a heterocyclic ring selected from the group consisting of l-piperidyl, l-pyrrolidyl, 4-morpholinyl and 1-loweralkyl-4-piperazinyl; and X and X are selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, halogen, trifiuoromethyl, hydroxyl, lower alkoxy, mercapto, loweralkyl mercapto, loweralkyl sulfonyl, sulfamoyl, loweralkyl sulfamoyl and diloweralkyl sulfamoyl.
2. A compound selected from the group consisting of compounds of the formula HO OH CHCHzOH NHR References Cited UNITED STATES PATENTS 2/ 1966 Kollonitsch et al. 260-240 X OTHER REFERENCES Chemical Abstracts, Volume 54, columns 3350 to 3351 (1960).
Index Chemicus, Volume 1, No. 6, N0. 1693, on page 26 (1961).
Provita et al., J. Med. and Pharm. Chem, Vol. 4, pages 411415 (1961).
JOHN D. RANDOLPH, Primary Examiner.

Claims (1)

1. A COMPOUND SELECTED FROM THE GROUP CONSISTING OF COMPOUNDS HAVING THE STRUCTURAL FORMULA
US296463A 1963-07-22 1963-07-22 Novel 10, 11-dihydro-10, 11-dihydroxy-(3-substituted aminopropylidene)-5h-dibenzo [a, d] cycloheptenes Expired - Lifetime US3390179A (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
US296463A US3390179A (en) 1963-07-22 1963-07-22 Novel 10, 11-dihydro-10, 11-dihydroxy-(3-substituted aminopropylidene)-5h-dibenzo [a, d] cycloheptenes
SE09743/67A SE332820B (en) 1963-07-22 1964-07-02
IL21665A IL21665A (en) 1963-07-22 1964-07-07 10,11-dihydroxy(or acyloxy)-dibenzo-cycloheptene derivatives
IL29677A IL29677A (en) 1963-07-22 1964-07-07 3alpha,12beta-dihydro-8-(3-substituted-amino-propylidene)-8h-dibenzo(3,4:6,7)-cyclohepta(1,2-d)-1,3-dioxole compounds and their preparation
GB35404/66A GB1074085A (en) 1963-07-22 1964-07-09 Dibenzocycloheptene compounds
GB35402/66A GB1074083A (en) 1963-07-22 1964-07-09 Dibenzocycloheptene compounds
GB28412/64A GB1074082A (en) 1963-07-22 1964-07-09 Dibenzocycloheptene compounds
GB35403/66A GB1074084A (en) 1963-07-22 1964-07-09 Dibenzocycloheptene compounds
BR160953/64A BR6460953D0 (en) 1963-07-22 1964-07-17 PROCESS FOR THE PREPARATION OF DIBENZE CHLORINE HEPTENES
BE650800D BE650800A (en) 1963-07-22 1964-07-20
DK362064AA DK127723B (en) 1963-07-22 1964-07-21 Analogous process for the preparation of trans-10,11-dihydro-10,11-dihydroxy-5 (3-dialkylaminopropylidene) -5H-dibenzo [a, d] cycloheptene compounds or acid addition salts thereof.
CH953364A CH494731A (en) 1963-07-22 1964-07-21 Process for the preparation of derivatives of dibenzocyclo-heptene
SE8875/64A SE320963B (en) 1963-07-22 1964-07-21
CH1882968A CH476677A (en) 1963-07-22 1964-07-21 Process for the preparation of 5-hydroxy-5- (3-tertiary-aminopropyl) derivatives
DE19641468339 DE1468339A1 (en) 1963-07-22 1964-07-21 Dibenzocycloheptane derivatives and processes for their preparation
CH1882868A CH490321A (en) 1963-07-22 1964-07-21 Process for the preparation of dibenzocycloheptenes
FR1572128D FR1572128A (en) 1963-07-22 1964-07-21
SE09742/67A SE332819B (en) 1963-07-22 1964-07-21
NL6408390A NL6408390A (en) 1963-07-22 1964-07-22
ES0302593A ES302593A1 (en) 1963-07-22 1964-07-22 Procedure for obtaining derivatives of dibenzocicloheptenes. (Machine-translation by Google Translate, not legally binding)
FR992062A FR3905M (en) 1963-07-22 1964-10-20
DK351165AA DK121757B (en) 1963-07-22 1965-07-09 Process for the preparation of 10,11-dihydro-10,11-dihydroxy-5- (3-substituted aminopropylidene) -5H-dibenzo- [a, d] -cycloheptene compounds.
DK351265AA DK121856B (en) 1963-07-22 1965-07-09 Analogous process for the preparation of 10,11-dihydro-10,11-dihydroxy-5- (3-monosubstituted aminopropylidene) -5H-dibenzo [a, d] -cycloheptene compounds.
US723964*A US3576823A (en) 1963-07-22 1968-01-29 Substituted derivative of 3alpha,12beta-dihydro-8h- -dibenzo(3,4:6,7)cyclohepta(1,2-d)-1,3-dioxole
US48478A US3660389A (en) 1963-07-22 1970-06-22 10 11 - diacyloxy - 10 11-dihydro-5-tertiary amino propyl - 5-hydroxy-5h-dibenzo(a d)cycloheptenes
DK168772A DK130736B (en) 1963-07-22 1972-04-07 Analogous process for the preparation of cis-10,11-dihydro-10,11-dihydroxy-5 (3-substituted aminopropylidene) -5H-dibenzo [a, d] cycloheptene compounds or acid addition salts thereof.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US296463A US3390179A (en) 1963-07-22 1963-07-22 Novel 10, 11-dihydro-10, 11-dihydroxy-(3-substituted aminopropylidene)-5h-dibenzo [a, d] cycloheptenes
US4847870A 1970-06-22 1970-06-22

Publications (1)

Publication Number Publication Date
US3390179A true US3390179A (en) 1968-06-25

Family

ID=26726156

Family Applications (2)

Application Number Title Priority Date Filing Date
US296463A Expired - Lifetime US3390179A (en) 1963-07-22 1963-07-22 Novel 10, 11-dihydro-10, 11-dihydroxy-(3-substituted aminopropylidene)-5h-dibenzo [a, d] cycloheptenes
US48478A Expired - Lifetime US3660389A (en) 1963-07-22 1970-06-22 10 11 - diacyloxy - 10 11-dihydro-5-tertiary amino propyl - 5-hydroxy-5h-dibenzo(a d)cycloheptenes

Family Applications After (1)

Application Number Title Priority Date Filing Date
US48478A Expired - Lifetime US3660389A (en) 1963-07-22 1970-06-22 10 11 - diacyloxy - 10 11-dihydro-5-tertiary amino propyl - 5-hydroxy-5h-dibenzo(a d)cycloheptenes

Country Status (11)

Country Link
US (2) US3390179A (en)
BE (1) BE650800A (en)
BR (1) BR6460953D0 (en)
CH (1) CH494731A (en)
DE (1) DE1468339A1 (en)
DK (3) DK127723B (en)
FR (2) FR1572128A (en)
GB (4) GB1074082A (en)
IL (2) IL21665A (en)
NL (1) NL6408390A (en)
SE (3) SE332820B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894032A (en) * 1974-04-10 1975-07-08 Merck & Co Inc 10,11-Furo derivatives of cyproheptadine
US3905981A (en) * 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US4044143A (en) * 1975-01-30 1977-08-23 Merck & Co., Inc. 10,11-Bis-(hydroxyalkyl) derivatives of cyproheptadine

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089864A (en) * 1974-03-25 1978-05-16 Merck & Co., Inc. 4-(10,11-Dihydro-cis and trans-10,11-dihydroxy-5H-dibenzo[a,d]cyclohepten-5-ylidene)-piperidines
DE4232173A1 (en) * 1992-09-25 1994-03-31 Bayer Ag 5-oxo-dibenzo (a, d) cyclohepta-1,4-diene

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234279A (en) * 1962-09-14 1966-02-08 Merck & Co Inc 5-(gamma-amino-propyl- and propylidene-) 5h-dibenzo[a, d]-10-hydroxy-10, 11-dihydrocycloheptenes and amine borane salts thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3234279A (en) * 1962-09-14 1966-02-08 Merck & Co Inc 5-(gamma-amino-propyl- and propylidene-) 5h-dibenzo[a, d]-10-hydroxy-10, 11-dihydrocycloheptenes and amine borane salts thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3905981A (en) * 1973-10-12 1975-09-16 Research Corp N-dealkylation of tertiary amines
US3894032A (en) * 1974-04-10 1975-07-08 Merck & Co Inc 10,11-Furo derivatives of cyproheptadine
US4044143A (en) * 1975-01-30 1977-08-23 Merck & Co., Inc. 10,11-Bis-(hydroxyalkyl) derivatives of cyproheptadine

Also Published As

Publication number Publication date
DK127723B (en) 1973-12-24
FR3905M (en) 1966-02-07
IL29677A (en) 1969-01-29
GB1074084A (en) 1967-06-28
GB1074083A (en) 1967-06-28
SE320963B (en) 1970-02-23
CH494731A (en) 1970-08-15
DK121856B (en) 1971-12-13
BR6460953D0 (en) 1973-08-02
GB1074085A (en) 1967-06-28
FR1572128A (en) 1969-06-27
US3660389A (en) 1972-05-02
SE332820B (en) 1971-02-22
BE650800A (en) 1965-01-20
SE332819B (en) 1971-02-22
DE1468339A1 (en) 1968-12-19
IL21665A (en) 1969-01-29
GB1074082A (en) 1967-06-28
NL6408390A (en) 1965-01-25
DK121757B (en) 1971-11-29

Similar Documents

Publication Publication Date Title
US3420851A (en) Novel dibenzoxepines
DK173923B1 (en) Azidosulphate
US2857385A (en) Preparation op pentacyclic lactones
US3120540A (en) Bis (polymethyl)-4-piperidinol alkanoates
US3825569A (en) Synthesis of tricyclic carbocyclic compounds and intermediates therefor
US3894031A (en) Indantetrol derivatives
US3390179A (en) Novel 10, 11-dihydro-10, 11-dihydroxy-(3-substituted aminopropylidene)-5h-dibenzo [a, d] cycloheptenes
US3314966A (en) Substituted benzo[a]quinolizines
US3637756A (en) Dioxaspiroalkanone propionic acids esters and nitriles thereof
US3631039A (en) 2-amino ethyl-2-hydroxy - 6-vinyl tetrahydropyrans tautomers and optical enantiomers thereof
US3646107A (en) Substituted 10 11-dihydro-5h-dibenzo(a d)cycloheptene esters
GB1568407A (en) Bicyclicpentol derivatives
US3576823A (en) Substituted derivative of 3alpha,12beta-dihydro-8h- -dibenzo(3,4:6,7)cyclohepta(1,2-d)-1,3-dioxole
US3720688A (en) Chemical compounds and methods of preparing the same
US3711518A (en) Chemical compounds and methods of preparing the same
US3317527A (en) 3a and 5a tertiaryamino cycloalkylene of 5 to 7[alpha]benzofuranols
US3028394A (en) 9-phenyl octahydroindole compounds and process of making same
Remy et al. A comparison of the antiserotonin, antihistamine, and anticholinergic activity of cyproheptadine with analogs having furan nuclei fused to the 10, 11-vinylene bridge
US4156694A (en) Benzobicyclononene derivatives
US3828034A (en) Tricyclic pharmacological agents,intermediates and methods of making
US3458518A (en) 10,5-(iminomethano)-10,11-dihydro-5h-dibenzo(a,d)cyclohepten-11-ones
US2986562A (en) Reserpic and deserpidic acid lactone dienes
US3539557A (en) 9,10 - dihydro - 13 - hydroxy - 9,10(methanoiminomethano) anthracen - 11 - one and its preparation
Clarke et al. In pursuit of analgetic agents. Hydro-1, 3-ethanoindeno [2, 1-c] pyridines and homologs
US3800044A (en) Pharmaceutical methods using a substituted 10-aminoalkyl-9,10-dihydroanthracene